These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 36047730)
21. Clinical characteristics of KCNQ2 encephalopathy. Kim HJ; Yang D; Kim SH; Won D; Kim HD; Lee JS; Choi JR; Lee ST; Kang HC Brain Dev; 2021 Feb; 43(2):244-250. PubMed ID: 32917465 [TBL] [Abstract][Full Text] [Related]
22. Novel KCNQ2 mutation in a large Emirati family with benign familial neonatal seizures. Saadeldin IY; Milhem RM; Al-Gazali L; Ali BR Pediatr Neurol; 2013 Jan; 48(1):63-6. PubMed ID: 23290024 [TBL] [Abstract][Full Text] [Related]
23. Homomeric Kv7.2 current suppression is a common feature in KCNQ2 epileptic encephalopathy. Gomis-Pérez C; Urrutia J; Marcé-Grau A; Malo C; López-Laso E; Felipe-Rucián A; Raspall-Chaure M; Macaya A; Villarroel A Epilepsia; 2019 Jan; 60(1):139-148. PubMed ID: 30478917 [TBL] [Abstract][Full Text] [Related]
24. A novel de novo KCNQ2 mutation in a child with treatmentresistant early-onset epileptic encephalopathy. Benetou C; Papailiou S; Maritsi D; Anagnostopoulou K; Kontos H; Vartzelis G Turk J Pediatr; 2019; 61(2):279-281. PubMed ID: 31951342 [TBL] [Abstract][Full Text] [Related]
26. Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filter. Nissenkorn A; Kornilov P; Peretz A; Blumkin L; Heimer G; Ben-Zeev B; Attali B Epileptic Disord; 2021 Oct; 23(5):695-705. PubMed ID: 34519644 [TBL] [Abstract][Full Text] [Related]
27. [A novel mutation in KCNQ2 gene causes benign familial infantile convulsions (BFIC) in a Chinese family]. Zhou XH; Ma AQ; Liu XH; Huang C; Zhang YM; Shi RM Zhonghua Er Ke Za Zhi; 2006 Jul; 44(7):487-91. PubMed ID: 17044971 [TBL] [Abstract][Full Text] [Related]
28. KCNQ2 encephalopathy: A case due to a de novo deletion. Spagnoli C; Salerno GG; Iodice A; Frattini D; Pisani F; Fusco C Brain Dev; 2018 Jan; 40(1):65-68. PubMed ID: 28728838 [TBL] [Abstract][Full Text] [Related]
30. Heterozygous loss of epilepsy gene KCNQ2 alters social, repetitive and exploratory behaviors. Kim EC; Patel J; Zhang J; Soh H; Rhodes JS; Tzingounis AV; Chung HJ Genes Brain Behav; 2020 Jan; 19(1):e12599. PubMed ID: 31283873 [TBL] [Abstract][Full Text] [Related]
31. Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. Miceli F; Soldovieri MV; Ambrosino P; De Maria M; Migliore M; Migliore R; Taglialatela M J Neurosci; 2015 Mar; 35(9):3782-93. PubMed ID: 25740509 [TBL] [Abstract][Full Text] [Related]
32. Early-onset epileptic encephalopathy caused by a reduced sensitivity of Kv7.2 potassium channels to phosphatidylinositol 4,5-bisphosphate. Soldovieri MV; Ambrosino P; Mosca I; De Maria M; Moretto E; Miceli F; Alaimo A; Iraci N; Manocchio L; Medoro A; Passafaro M; Taglialatela M Sci Rep; 2016 Dec; 6():38167. PubMed ID: 27905566 [TBL] [Abstract][Full Text] [Related]
33. A recurrent KCNQ2 pore mutation causing early onset epileptic encephalopathy has a moderate effect on M current but alters subcellular localization of Kv7 channels. Abidi A; Devaux JJ; Molinari F; Alcaraz G; Michon FX; Sutera-Sardo J; Becq H; Lacoste C; Altuzarra C; Afenjar A; Mignot C; Doummar D; Isidor B; Guyen SN; Colin E; De La Vaissière S; Haye D; Trauffler A; Badens C; Prieur F; Lesca G; Villard L; Milh M; Aniksztejn L Neurobiol Dis; 2015 Aug; 80():80-92. PubMed ID: 26007637 [TBL] [Abstract][Full Text] [Related]
34. Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review. Chen J; Tao Q; Fan L; Shen Y; Liu J; Luo H; Yang Z; Liang M; Gan J Mol Genet Genomic Med; 2022 Oct; 10(10):e2024. PubMed ID: 35906921 [TBL] [Abstract][Full Text] [Related]
35. KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism. Miceli F; Millevert C; Soldovieri MV; Mosca I; Ambrosino P; Carotenuto L; Schrader D; Lee HK; Riviello J; Hong W; Risen S; Emrick L; Amin H; Ville D; Edery P; de Bellescize J; Michaud V; Van-Gils J; Goizet C; Willemsen MH; Kleefstra T; Møller RS; Bayat A; Devinsky O; Sands T; Korenke GC; Kluger G; Mefford HC; Brilstra E; Lesca G; Milh M; Cooper EC; Taglialatela M; Weckhuysen S EBioMedicine; 2022 Jul; 81():104130. PubMed ID: 35780567 [TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo anti-epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2-related self-limited epilepsy. Monni L; Kraus L; Dipper-Wawra M; Soares-da-Silva P; Maier N; Schmitz D; Holtkamp M; Fidzinski P Br J Pharmacol; 2022 Jan; 179(1):84-102. PubMed ID: 34605012 [TBL] [Abstract][Full Text] [Related]
40. KCNQ2 mutations in childhood nonlesional epilepsy: Variable phenotypes and a novel mutation in a case series. Lee IC; Chang TM; Liang JS; Li SY Mol Genet Genomic Med; 2019 Jul; 7(7):e00816. PubMed ID: 31199083 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]